Literature DB >> 30859013

Hemorrhagic stroke complicated by cerebral venous sinus thrombosis with idarucizumab.

Chun Seng Phua1, Andrew Bonura1, Ho Choong1.   

Abstract

Entities:  

Year:  2019        PMID: 30859013      PMCID: PMC6382382          DOI: 10.1212/CPJ.0000000000000555

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  3 in total

1.  A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

Authors:  Stephan Glund; Viktoria Moschetti; Stephen Norris; Joachim Stangier; Michael Schmohl; Joanne van Ryn; Benjamin Lang; Steven Ramael; Paul Reilly
Journal:  Thromb Haemost       Date:  2015-03-19       Impact factor: 5.249

2.  Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Authors:  Charles V Pollack; Paul A Reilly; Joanne van Ryn; John W Eikelboom; Stephan Glund; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Chak-Wah Kam; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Gordon Royle; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Peter Verhamme; Bushi Wang; Laura Young; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2017-07-11       Impact factor: 91.245

3.  Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Authors:  Stephan Glund; Joachim Stangier; Joanne van Ryn; Michael Schmohl; Viktoria Moschetti; Wouter Haazen; Marina De Smet; Dietmar Gansser; Stephen Norris; Benjamin Lang; Paul Reilly; Jörg Kreuzer
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

  3 in total
  1 in total

1.  Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series.

Authors:  Senta Frol; Dimitrios Sagris; Mišo Šabovič; George Ntaios; Janja Pretnar Oblak
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.